Jocelyn Nikita Campa-Carranza

Jocelyn Nikita Campa-Carranza

Auto-generated profile, based on publicly available information

Jocelyn Nikita Campa-Carranza

Center for BioNanoengineering Houston Methodist Research Institute Houston Texas USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 December 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
JPJesus Paez-Mayorga
Jesus Paez-Mayorga
JCJocelyn Nikita Campa-Carranza
Jocelyn Nikita Campa-Carranza
SCSimone Capuani
Simone Capuani
NHNathanael Hernandez
Nathanael Hernandez
HLHsuan-Chen Liu
Hsuan-Chen Liu
Alessandro GrattoniAlessandro Grattoni
Alessandro Grattoni
Pancreatic islet transplantation efficacy for type 1 diabetes (T1D) management is limited by hypoxia-related graft attrition and need for systemic immunosuppression. To overcome these challenges, we developed the Neovascularized Implantable Cell Homing and Encapsulation (NICHE) device, which integrates direct vascularization for facile mass transfer and localized immunosuppressant delivery for islet rejection prophylaxis. Here, we investigated NICHE efficacy for allogeneic islet transplantation and long-term diabetes reversal in an immunocompetent, male rat model. We demonstrated that allogeneic islets transplanted within pre-vascularized NICHE were engrafted, revascularized, and functional, reverting diabetes in rats for over 150 days. Notably, we confirmed that localized immunosuppression prevented islet rejection without inducing toxicity or systemic immunosuppression. Moreover, for translatability efforts, we showed NICHE biocompatibility and feasibility of deployment as well as short-term allogeneic islet engraftment in an MHC-mismatched nonhuman primate model. In sum, the NICHE holds promise as a viable approach for safe and effective islet transplantation and long-term T1D management.

28 June 2023 in Science Translational Medicine
Verified
Journal Article
Closed access
FPFernanda P. Pons-Faudoa
Fernanda P. Pons-Faudoa
NTNicola Di Trani
Nicola Di Trani
SCSimone Capuani
Simone Capuani
JCJocelyn Nikita Campa-Carranza
Jocelyn Nikita Campa-Carranza
BNBharti Nehete
Bharti Nehete
Alessandro GrattoniAlessandro Grattoni
Alessandro Grattoni
The impact of pre-exposure prophylaxis (PrEP) on slowing the global HIV epidemic hinges on effective drugs and delivery platforms. Oral drug regimens are the pillar of HIV PrEP, but variable adherence has spurred development of long-acting delivery systems with the aim of increasing PrEP access, uptake, and persistence. We have developed a long-acting subcutaneous nanofluidic implant that can be refilled transcutaneously for sustained release of the HIV drug islatravir, a nucleoside reverse transcriptase translocation inhibitor that is used for HIV PrEP. In rhesus macaques, the islatravir-eluting implants achieved constant concentrations of islatravir in plasma (median 3.14 nM) and islatravir triphosphate in peripheral blood mononuclear cells (median 0.16 picomole per 10 6 cells) for more than 20 months. These drug concentrations were above the established PrEP protection threshold. In two unblinded, placebo-controlled studies, islatravir-eluting implants conferred 100% protection against infection with SHIV SF162P3 after repeated low-dose rectal or vaginal challenge in male or female rhesus macaques, respectively, compared to placebo control groups. The islatravir-eluting implants were well tolerated with mild local tissue inflammation and no signs of systemic toxicity over the 20-month study period. This refillable islatravir-eluting implant has potential as a long-acting drug delivery system for HIV PrEP.

8 May 2025 in Advanced Science
Verified
Journal Article
Open access
JCJocelyn Nikita Campa‐Carranza
Jocelyn Nikita Campa‐Carranza
SCSimone Capuani
Simone Capuani
AJAshley L. Joubert
Ashley L. Joubert
NHNathanael Hernandez
Nathanael Hernandez
TBTommaso Bo
Tommaso Bo
Alessandro GrattoniAlessandro Grattoni
Alessandro Grattoni
Islet transplantation offers a promising treatment for type 1 diabetes (T1D), by aiming to restore insulin production and improve glycemic control. However, T1D is compounded by impaired angiogenesis and immune dysregulation, which hinder the therapeutic potential of cell replacement strategies. To address this, this work evaluates the proangiogenic and immunomodulatory properties of mesenchymal stem cells (MSCs) to enhance vascularization and modulate early‐stage immune rejection pathways in the context of islet allotransplantation. This work employs the Neovascularized Implantable Cell Homing and Encapsulation (NICHE) platform, a subcutaneous vascularized implant with localized immunomodulation developed by the group. This study assesses vascularization and immune regulation provided by MSCs, aiming to improve islet survival and integration in diabetic rats while considering sex as a biological variable. These findings demonstrate that MSCs significantly enhance vascularization and modulate the local microenvironment during the peri‐transplant period. Importantly, this work discovers sex‐specific differences in both processes, which influence islet engraftment and long‐term function.

6 March 2026 in Advanced Science
Verified
Journal Article
Open access
JCJocelyn Nikita Campa‐Carranza
Jocelyn Nikita Campa‐Carranza
SCSimone Capuani
Simone Capuani
MWMelissa A. Willman
Melissa A. Willman
ARAlexander Rabassa
Alexander Rabassa
AJAshley L. Joubert
Ashley L. Joubert
Alessandro GrattoniAlessandro Grattoni
Alessandro Grattoni
Systemic immunosuppression remains essential for preventing allogeneic transplant rejection, but its chronic use causes substantial toxicity. Conceptually, local, site‐specific immunomodulation offers a promising alternative, yet comparative mechanistic insight into how immunosuppressants behave when delivered directly to the graft is lacking. Here, we leveraged the Neovascularized Implantable Cell Homing and Encapsulation (NICHE) device, a subcutaneous, vascularized cell‐encapsulation platform, as a spatially defined and reproducible model to study local immunomodulation in allogeneic islet transplantation. We systematically profiled the safety, local and systemic immunomodulatory effects, pharmacokinetics, and longitudinal biodistribution of five clinically relevant agents delivered locally at the graft site: CTLA4‐Ig, anti‐lymphocyte serum, anti‐CD40L, anti‐CD2, and anti‐IL6. Sustained in situ exposure did not impair islet viability or function, and immunosuppressants were confined within the graft, with up to 100‐fold lower systemic concentrations. Individual agents produced distinct immune signatures, spanning lymphocyte depletion and shifts in T‐cell activation that can guide rational, mechanism‐informed combinations for allogeneic cell transplantation. These findings provide a comparative framework for evaluating localized immunosuppression with the potential to transform immunoprotection in cell therapy.